- Home
- SNT vs CCCC Comparison
SNT vs CCCC Comparison
Compare SNT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- CCCC
- Stock Information
- Founded
- SNT 1965
- CCCC 2015
- Country
- SNT Canada
- CCCC United States
- Employees
- SNT N/A
- CCCC N/A
- Industry
- SNT Telecommunications Equipment
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- CCCC Health Care
- Exchange
- SNT Nasdaq
- CCCC Nasdaq
- Market Cap
- SNT 95.2M
- CCCC 104.4M
- IPO Year
- SNT 1993
- CCCC 2020
- Fundamental
- Price
- SNT $4.44
- CCCC $2.26
- Analyst Decision
- SNT
- CCCC Buy
- Analyst Count
- SNT 0
- CCCC 3
- Target Price
- SNT N/A
- CCCC $12.00
- AVG Volume (30 Days)
- SNT 66.9K
- CCCC 2.0M
- Earning Date
- SNT 08-25-2025
- CCCC 08-04-2025
- Dividend Yield
- SNT N/A
- CCCC N/A
- EPS Growth
- SNT N/A
- CCCC N/A
- EPS
- SNT 0.18
- CCCC N/A
- Revenue
- SNT $36,690,000.00
- CCCC $39,783,000.00
- Revenue This Year
- SNT N/A
- CCCC N/A
- Revenue Next Year
- SNT N/A
- CCCC N/A
- P/E Ratio
- SNT $24.67
- CCCC N/A
- Revenue Growth
- SNT 8.36
- CCCC 98.56
- 52 Week Low
- SNT $1.40
- CCCC $1.09
- 52 Week High
- SNT $5.04
- CCCC $7.36
- Technical
- Relative Strength Index (RSI)
- SNT 48.89
- CCCC 60.73
- Support Level
- SNT $4.27
- CCCC $2.15
- Resistance Level
- SNT $4.70
- CCCC $2.53
- Average True Range (ATR)
- SNT 0.26
- CCCC 0.28
- MACD
- SNT -0.06
- CCCC 0.02
- Stochastic Oscillator
- SNT 30.43
- CCCC 62.13
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.